ProPhase Labs, Inc. (PRPH) P/E Ratio History
Deep ValueTrading at -0.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1997–2023
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, ProPhase Labs, Inc. (PRPH) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.01 and trailing twelve-month earnings per share of $-1.62.
The current P/E is 100% below its 5-year average of 147.2x. Over the past five years, PRPH's P/E has ranged from a low of 1.8x to a high of 1037.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, PRPH trades at a 100% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.
Relative to the broader market, PRPH trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PRPH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PRPH Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PRPH P/E vs Peers
Consumer health and OTC self-care peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $247B | 37.5 | 17.76 | +7%Best | |
| $156B | 44.0 | - | -5% | |
| $47B | 36.2Lowest | 2.46Best | +3% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PRPH Historical P/E Data (1997–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q1 | Mar 31 2023 | $38.10 | $3.22 | 11.8x | -91% |
| FY2022 Q4 | Dec 31 2022 | $48.20 | $9.58 | 5.0x | -96% |
| FY2022 Q3 | Sep 30 2022 | $56.40 | $17.98 | 3.1x | -98% |
| FY2022 Q2 | - | $63.40 | $14.90 | 4.3x | -97% |
| FY2022 Q1 | - | $35.00 | $10.08 | 3.5x | -97% |
| FY2021 Q4 | Dec 31 2021 | $35.90 | $3.98 | 9.0x | -93% |
| FY2017 Q4 | Dec 31 2017 | $43.40 | $22.99 | 1.9x | -99% |
| FY2017 Q3 | Sep 30 2017 | $42.80 | $22.48 | 1.9x | -99% |
| FY2017 Q2 | Jun 30 2017 | $41.80 | $23.07 | 1.8x | -99% |
| FY2017 Q1 | Mar 31 2017 | $45.40 | $23.80 | 1.9x | -99% |
| FY2013 Q4 | - | $32.20 | $0.26 | 122.4x | -10% |
| FY2013 Q3 | Sep 30 2013 | $38.00 | $0.20 | 190.0x | +39% |
| FY2013 Q2 | Jun 30 2013 | $31.00 | $0.10 | 310.0x | +127% |
| FY2006 Q2 | Jun 30 2006 | $183.40 | $0.80 | 229.3x | +68% |
| FY2006 Q1 | Mar 31 2006 | $168.60 | $1.40 | 120.4x | -12% |
| FY2005 Q4 | Dec 31 2005 | $276.40 | $2.47 | 112.0x | -18% |
| FY2005 Q3 | Sep 30 2005 | $180.40 | $2.37 | 76.2x | -44% |
| FY2005 Q2 | - | $173.20 | $0.17 | 1037.1x | +661% |
| FY2005 Q1 | - | $165.20 | $0.87 | 189.0x | +39% |
| FY2004 Q4 | Dec 31 2004 | $168.60 | $0.33 | 514.0x | +277% |
| FY2004 Q3 | - | $166.80 | $0.83 | 201.4x | +48% |
| FY2004 Q2 | Jun 30 2004 | $199.40 | $0.83 | 240.8x | +77% |
| FY2004 Q1 | Mar 31 2004 | $197.00 | $0.70 | 281.4x | +106% |
| FY2003 Q4 | Dec 31 2003 | $212.80 | $0.55 | 384.8x | +182% |
| FY2001 Q4 | Dec 31 2001 | $46.00 | $0.21 | 220.1x | +61% |
| FY1999 Q2 | Jun 30 1999 | $98.10 | $1.50 | 65.4x | -52% |
| FY1999 Q1 | Mar 31 1999 | $102.50 | $2.50 | 41.0x | -70% |
| FY1998 Q4 | - | $110.60 | $4.80 | 23.0x | -83% |
| FY1998 Q3 | Sep 30 1998 | $145.00 | $9.80 | 14.8x | -89% |
| FY1998 Q2 | - | $142.50 | $11.40 | 12.5x | -91% |
| FY1998 Q1 | - | $225.00 | $12.34 | 18.2x | -87% |
| FY1997 Q4 | Dec 31 1997 | $288.80 | $17.04 | 16.9x | -88% |
| FY1997 Q3 | - | $380.00 | $11.24 | 33.8x | -75% |
Average P/E for displayed period: 136.3x
PRPH Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
29+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PRPH — Frequently Asked Questions
Quick answers to the most common questions about buying PRPH stock.
What is PRPH's P/E ratio?
ProPhase Labs, Inc. (PRPH) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-1.62. The 5-year average P/E is 147.2x and the historical range spans 1.8x to 1037.1x.
Is PRPH stock overvalued or undervalued?
PRPH current P/E: -0.0x. 5-year average P/E: 147.2x. Percentile: 0th.
Is PRPH stock expensive?
PRPH is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of 147.2x (0th percentile of historical range).
What is PRPH's historical P/E range?
Over the past 5 years, PRPH's P/E ratio has ranged from 1.8x to 1037.1x, with a median of 76.2x and an average of 147.2x. The current P/E of -0.0x places the stock at the 0th percentile of this range. Full historical data spans 1997–2023.
How does PRPH's P/E compare to the S&P 500?
PRPH current P/E: -0.0x. S&P 500 median P/E: 25.3x.
How does PRPH's valuation compare to Healthcare peers?
ProPhase Labs, Inc. P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is PRPH's PEG ratio?
PRPH PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 93.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is PRPH's earnings yield?
PRPH earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.